Ji Jinming, Li Gang, Ma Yunxia, Pan Shuangshuang, Yuan Rongrong
Dept. of Neurology, Binzhou People's Hospital, Binzhou, Shandong, China.
Dept. of Neurology, Binzhou City Center Hospital, Binzhou, Shandong, China.
Iran J Public Health. 2018 Jan;47(1):40-48.
We aimed to investigate the expression levels of multidrug resistance gene 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance P-glycoprotein (P-gp) in peripheral blood of patients with refractory epilepsy.
Patients with epilepsy (n=24) and those with refractory epilepsy (n=24) were selected, and 30 normal volunteers were enrolled as control. The expression level of MDR1 genes was detected using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). The expression levels of P-gp and MRP1 were detected via Western blotting. The above-mentioned patients with refractory epilepsy were randomly divided into the oxcarbazepine group (OB group) and placebo group (OZ group). After consecutive 8-week oral administration of drugs, the curative effect and adverse reactions of patients with refractory epilepsy were observed, and the life quality of patients was evaluated.
The expression levels of MDR1 genes, P-gp and MRP1 in peripheral blood of patients with refractory epilepsy were significantly increased compared with those of patients with epilepsy, (<0.05). At 8 weeks after the drug therapy, the effective rate and life quality of patients in OB group were significantly higher than those of patients in OZ group (<0.01). There was no significant difference in the incidence rate of adverse reactions during the treatment between the two groups. After treatment, the expression levels of MDR1, P-gp and MRP1 in peripheral blood of patients in OB group were significantly lower than those of patients in OZ group (<0.01).
Oxacillipine could effectively improve the effective treatment rate of patients with refractory epilepsy. The mechanism may be related to MDR1, MRP1 and Pgp expression.
我们旨在研究难治性癫痫患者外周血中多药耐药基因1（MDR1）、多药耐药相关蛋白1（MRP1）和多药耐药P-糖蛋白（P-gp）的表达水平。
选取癫痫患者（n = 24）和难治性癫痫患者（n = 24），并纳入30名正常志愿者作为对照。采用半定量逆转录-聚合酶链反应（RT-PCR）检测MDR1基因的表达水平。通过蛋白质免疫印迹法检测P-gp和MRP1的表达水平。将上述难治性癫痫患者随机分为奥卡西平组（OB组）和安慰剂组（OZ组）。连续口服药物8周后，观察难治性癫痫患者的疗效和不良反应，并评估患者的生活质量。
与癫痫患者相比，难治性癫痫患者外周血中MDR1基因、P-gp和MRP1的表达水平显著升高（<0.05）。药物治疗8周后，OB组患者的有效率和生活质量显著高于OZ组患者（<0.01）。两组治疗期间不良反应发生率无显著差异。治疗后，OB组患者外周血中MDR1、P-gp和MRP1的表达水平显著低于OZ组患者（<0.01）。
奥卡西平可有效提高难治性癫痫患者的有效治疗率。其机制可能与MDR1、MRP1和Pgp的表达有关。
